152 related articles for article (PubMed ID: 34767372)
1. A Duplex CRISPR-Cas9 Ribonucleoprotein Nanomedicine for Colorectal Cancer Gene Therapy.
Wan T; Pan Q; Liu C; Guo J; Li B; Yan X; Cheng Y; Ping Y
Nano Lett; 2021 Nov; 21(22):9761-9771. PubMed ID: 34767372
[TBL] [Abstract][Full Text] [Related]
2. Genome editing of mutant KRAS through supramolecular polymer-mediated delivery of Cas9 ribonucleoprotein for colorectal cancer therapy.
Wan T; Chen Y; Pan Q; Xu X; Kang Y; Gao X; Huang F; Wu C; Ping Y
J Control Release; 2020 Jun; 322():236-247. PubMed ID: 32169537
[TBL] [Abstract][Full Text] [Related]
3. Interaction of the Wnt/β-catenin and RAS-ERK pathways involving co-stabilization of both β-catenin and RAS plays important roles in the colorectal tumorigenesis.
Lee SK; Hwang JH; Choi KY
Adv Biol Regul; 2018 May; 68():46-54. PubMed ID: 29449169
[TBL] [Abstract][Full Text] [Related]
4. A mutant KRAS-induced factor REG4 promotes cancer stem cell properties via Wnt/β-catenin signaling.
Hwang JH; Yoon J; Cho YH; Cha PH; Park JC; Choi KY
Int J Cancer; 2020 May; 146(10):2877-2890. PubMed ID: 31605540
[TBL] [Abstract][Full Text] [Related]
5. A small molecule approach to degrade RAS with EGFR repression is a potential therapy for KRAS mutation-driven colorectal cancer resistance to cetuximab.
Lee SK; Cho YH; Cha PH; Yoon JS; Ro EJ; Jeong WJ; Park J; Kim H; Il Kim T; Min DS; Han G; Choi KY
Exp Mol Med; 2018 Nov; 50(11):1-12. PubMed ID: 30459318
[TBL] [Abstract][Full Text] [Related]
6. In Colorectal Cancer Cells With Mutant KRAS, SLC25A22-Mediated Glutaminolysis Reduces DNA Demethylation to Increase WNT Signaling, Stemness, and Drug Resistance.
Wong CC; Xu J; Bian X; Wu JL; Kang W; Qian Y; Li W; Chen H; Gou H; Liu D; Yat Luk ST; Zhou Q; Ji F; Chan LS; Shirasawa S; Sung JJ; Yu J
Gastroenterology; 2020 Dec; 159(6):2163-2180.e6. PubMed ID: 32814111
[TBL] [Abstract][Full Text] [Related]
7. Quadruple-editing of the MAPK and PI3K pathways effectively blocks the progression of KRAS-mutated colorectal cancer cells.
Wang Z; Kang B; Gao Q; Huang L; Di J; Fan Y; Yu J; Jiang B; Gao F; Wang D; Sun H; Gu Y; Li J; Su X
Cancer Sci; 2021 Sep; 112(9):3895-3910. PubMed ID: 34185934
[TBL] [Abstract][Full Text] [Related]
8. ARID1A facilitates KRAS signaling-regulated enhancer activity in an AP1-dependent manner in colorectal cancer cells.
Sen M; Wang X; Hamdan FH; Rapp J; Eggert J; Kosinsky RL; Wegwitz F; Kutschat AP; Younesi FS; Gaedcke J; Grade M; Hessmann E; Papantonis A; Strӧbel P; Johnsen SA
Clin Epigenetics; 2019 Jun; 11(1):92. PubMed ID: 31217031
[TBL] [Abstract][Full Text] [Related]
9. Interaction between Wnt/β-catenin and RAS-ERK pathways and an anti-cancer strategy via degradations of β-catenin and RAS by targeting the Wnt/β-catenin pathway.
Jeong WJ; Ro EJ; Choi KY
NPJ Precis Oncol; 2018; 2(1):5. PubMed ID: 29872723
[TBL] [Abstract][Full Text] [Related]
10. Editing the immune system in vivo in mice using CRISPR/Cas9 ribonucleoprotein (RNP)-mediated gene editing of transplanted hematopoietic stem cells.
Wang R; Graham S; Gao L; Tam J; Levesque MC
Methods; 2021 Oct; 194():30-36. PubMed ID: 33422676
[TBL] [Abstract][Full Text] [Related]
11. Direct Cytosolic Delivery of CRISPR/Cas9-Ribonucleoprotein for Efficient Gene Editing.
Mout R; Ray M; Yesilbag Tonga G; Lee YW; Tay T; Sasaki K; Rotello VM
ACS Nano; 2017 Mar; 11(3):2452-2458. PubMed ID: 28129503
[TBL] [Abstract][Full Text] [Related]
12. Adenomatous Polyposis Coli as a Major Regulator of Human Embryonic Stem Cells Self-Renewal.
Preisler L; Ben-Yosef D; Mayshar Y
Stem Cells; 2019 Dec; 37(12):1505-1515. PubMed ID: 31461190
[TBL] [Abstract][Full Text] [Related]
13. CRISPR/Cas9: a powerful tool in colorectal cancer research.
Hu Y; Liu L; Jiang Q; Fang W; Chen Y; Hong Y; Zhai X
J Exp Clin Cancer Res; 2023 Nov; 42(1):308. PubMed ID: 37993945
[TBL] [Abstract][Full Text] [Related]
14. Brain-targeted CRISPR/Cas9 nanomedicine for effective glioblastoma therapy.
Ruan W; Jiao M; Xu S; Ismail M; Xie X; An Y; Guo H; Qian R; Shi B; Zheng M
J Control Release; 2022 Nov; 351():739-751. PubMed ID: 36174804
[TBL] [Abstract][Full Text] [Related]
15. CRISPR-Cas9-mediated gene knockout in intestinal tumor organoids provides functional validation for colorectal cancer driver genes.
Takeda H; Kataoka S; Nakayama M; Ali MAE; Oshima H; Yamamoto D; Park JW; Takegami Y; An T; Jenkins NA; Copeland NG; Oshima M
Proc Natl Acad Sci U S A; 2019 Jul; 116(31):15635-15644. PubMed ID: 31300537
[TBL] [Abstract][Full Text] [Related]
16. MEK inhibitors activate Wnt signalling and induce stem cell plasticity in colorectal cancer.
Zhan T; Ambrosi G; Wandmacher AM; Rauscher B; Betge J; Rindtorff N; Häussler RS; Hinsenkamp I; Bamberg L; Hessling B; Müller-Decker K; Erdmann G; Burgermeister E; Ebert MP; Boutros M
Nat Commun; 2019 May; 10(1):2197. PubMed ID: 31097693
[TBL] [Abstract][Full Text] [Related]
17. USP7 Is a Tumor-Specific WNT Activator for APC-Mutated Colorectal Cancer by Mediating β-Catenin Deubiquitination.
Novellasdemunt L; Foglizzo V; Cuadrado L; Antas P; Kucharska A; Encheva V; Snijders AP; Li VSW
Cell Rep; 2017 Oct; 21(3):612-627. PubMed ID: 29045831
[TBL] [Abstract][Full Text] [Related]
18. MicroRNA-494 promotes cancer progression and targets adenomatous polyposis coli in colorectal cancer.
Zhang Y; Guo L; Li Y; Feng GH; Teng F; Li W; Zhou Q
Mol Cancer; 2018 Jan; 17(1):1. PubMed ID: 29304823
[TBL] [Abstract][Full Text] [Related]
19. Biomimetic Mineralization-Based CRISPR/Cas9 Ribonucleoprotein Nanoparticles for Gene Editing.
Li S; Song Z; Liu C; Chen XL; Han H
ACS Appl Mater Interfaces; 2019 Dec; 11(51):47762-47770. PubMed ID: 31773942
[TBL] [Abstract][Full Text] [Related]
20. TRIB3 Interacts With β-Catenin and TCF4 to Increase Stem Cell Features of Colorectal Cancer Stem Cells and Tumorigenesis.
Hua F; Shang S; Yang YW; Zhang HZ; Xu TL; Yu JJ; Zhou DD; Cui B; Li K; Lv XX; Zhang XW; Liu SS; Yu JM; Wang F; Zhang C; Huang B; Hu ZW
Gastroenterology; 2019 Feb; 156(3):708-721.e15. PubMed ID: 30365932
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
